RU2625768C2 - Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы - Google Patents

Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы Download PDF

Info

Publication number
RU2625768C2
RU2625768C2 RU2013109415A RU2013109415A RU2625768C2 RU 2625768 C2 RU2625768 C2 RU 2625768C2 RU 2013109415 A RU2013109415 A RU 2013109415A RU 2013109415 A RU2013109415 A RU 2013109415A RU 2625768 C2 RU2625768 C2 RU 2625768C2
Authority
RU
Russia
Prior art keywords
fucose
fucosylation
group
cells
aryl
Prior art date
Application number
RU2013109415A
Other languages
English (en)
Russian (ru)
Other versions
RU2013109415A (ru
Inventor
Питер Сентер
Стефен АЛЛЕЙ
Деннис БЕНДЖАМИН
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Publication of RU2013109415A publication Critical patent/RU2013109415A/ru
Application granted granted Critical
Publication of RU2625768C2 publication Critical patent/RU2625768C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
RU2013109415A 2010-08-05 2011-08-05 Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы RU2625768C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37111610P 2010-08-05 2010-08-05
US61/371,116 2010-08-05
PCT/US2011/046857 WO2012019165A2 (en) 2010-08-05 2011-08-05 Methods of inhibition of protein fucosylation in vivo using fucose analogs

Related Child Applications (1)

Application Number Title Priority Date Filing Date
RU2017122482A Division RU2017122482A (ru) 2010-08-05 2011-08-05 Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы

Publications (2)

Publication Number Publication Date
RU2013109415A RU2013109415A (ru) 2014-09-10
RU2625768C2 true RU2625768C2 (ru) 2017-07-18

Family

ID=45560106

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2013109415A RU2625768C2 (ru) 2010-08-05 2011-08-05 Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы
RU2017122482A RU2017122482A (ru) 2010-08-05 2011-08-05 Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2017122482A RU2017122482A (ru) 2010-08-05 2011-08-05 Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы

Country Status (21)

Country Link
US (4) US9504702B2 (enExample)
EP (2) EP2608796B1 (enExample)
JP (4) JP5918235B2 (enExample)
KR (2) KR20190022884A (enExample)
CN (2) CN107007615A (enExample)
AU (3) AU2011285490B2 (enExample)
CA (1) CA2803388C (enExample)
CY (1) CY1121419T1 (enExample)
DK (1) DK2608796T3 (enExample)
ES (1) ES2711622T3 (enExample)
HU (1) HUE043370T2 (enExample)
IL (2) IL224487A (enExample)
MX (1) MX356671B (enExample)
NZ (1) NZ606250A (enExample)
PL (1) PL2608796T3 (enExample)
PT (1) PT2608796T (enExample)
RU (2) RU2625768C2 (enExample)
SI (1) SI2608796T1 (enExample)
TR (1) TR201902439T4 (enExample)
WO (1) WO2012019165A2 (enExample)
ZA (1) ZA201300653B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
SI2608796T1 (sl) * 2010-08-05 2019-03-29 Seattle Genetics, Inc. Inhibicija proteinske fukozilacije in vivo z uporabo fukoznih analogov
US10350228B2 (en) * 2012-08-23 2019-07-16 Seattle Genetics, Inc. Treatment of sickle cell disease and inflammatory conditions
EP2958905B1 (en) 2013-02-22 2017-03-29 Amgen Inc. Carbohydrate phosphonate derivatives as modulators of glycosylation
CN106699886A (zh) * 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
CA3005997A1 (en) * 2015-12-04 2017-06-08 Seattle Genetics, Inc. Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor
EP3455363B1 (en) * 2016-05-10 2021-12-08 Ares Trading S.A. Methods for modulating protein galactosylation profiles of recombinant proteins using peracetyl galactose
JP2018002666A (ja) * 2016-07-04 2018-01-11 国立研究開発法人理化学研究所 フコース類似体と糖を検出する方法
MX2019014584A (es) * 2017-06-07 2020-02-07 Seattle Genetics Inc Celulas t con fucosilacion de superficie reducida y metodos para preparar y usar las mismas.
MX2020005662A (es) 2017-12-01 2020-08-20 Pfizer Anticuerpos anti-cxcr5 y composiciones y usos de los mismos.
MX2020010183A (es) 2018-03-29 2022-11-28 Pfizer Variantes y composiciones del lfa3 y sus usos.
WO2020041541A2 (en) 2018-08-23 2020-02-27 Seattle Genetics, Inc. Anti-tigit antibodies
JP7446587B2 (ja) * 2018-12-27 2024-03-12 慶應義塾 抗ヒトノロウイルス剤
WO2021122738A1 (en) * 2019-12-19 2021-06-24 Merck Patent Gmbh Methods and compositions for modulating the glycosylation profile of proteins
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
IL298746A (en) * 2020-06-03 2023-02-01 Univ Fraser Simon Inhibitors of protein fucosylation and their uses
EP4308170A1 (en) 2021-03-18 2024-01-24 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
CA3222409A1 (en) 2021-06-07 2022-12-15 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
US12116382B2 (en) 2022-11-28 2024-10-15 Hongene Biotech Corporation Functionalized N-acetylgalactosamine analogs
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019632A1 (en) * 1991-04-30 1992-11-12 The Biomembrane Institute Trifluoromethyl analogs of fucose and uses thereof
WO1998018805A2 (en) * 1996-10-28 1998-05-07 Novartis Ag Sugar derivatives as sialyl lewis x mimetics

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440780A (en) 1979-06-01 1984-04-03 Chevron Research Company Fungicidal 3-(N-acyl-N-arylamino)-and 3-(N-thionoacyl-N-arylamino)-gamma-butyrolactones and gamma-thiobutyrolactones
JPH0660189B2 (ja) 1986-01-22 1994-08-10 財団法人微生物化学研究会 ２，６−ジデオキシ−２−フルオロ−ｌ−タロピラノ−ス又はその誘導体とその製造法
FR2630914A1 (fr) 1988-05-04 1989-11-10 Hoechst Sa Laboratoires Nouveaux analogues du l-fucose, leur procede de preparation, application de ces analogues a la preparation de nouveaux glycals, anthracyclines obtenues a l'aide de ces glycals et utilisation desdites anthracyclines en tant que medicaments
KR100211417B1 (ko) 1990-11-30 1999-10-01 유충식 L-탈로피라노시드 유도체 및 그의 제조방법
US5461143A (en) 1991-03-18 1995-10-24 The Scripps Research Institute Oligosaccharide enzyme substrates and inhibitors: methods and compositions
DE69228005T2 (de) 1991-10-15 1999-07-15 The Scripps Research Institute, La Jolla, Calif. Herstellung von fucosylierten Kohlenhydraten durch enzymatische Fucosylierungs-Synthese der Zuckernukleotide; und in situ Regeneration von GDP-fucose
EP0721956B1 (en) 1993-09-29 2000-08-02 Nissin Shokuhin Kabushiki Kaisha 21-substituted steroid compound
US5481143A (en) 1993-11-15 1996-01-02 Burdick; Brian K. Self starting brushless d.c. motor
FR2723947B1 (fr) 1994-08-31 1996-09-27 Adir Nouveaux composes tetrahydropyraniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19524515A1 (de) 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US6713287B1 (en) 1995-10-24 2004-03-30 The Scripps Research Institute Enzymatic synthesis of L-fucose and L-fucose analogs
US5770407A (en) 1996-12-10 1998-06-23 The Scripps Research Institute Process for preparing nucleotide inhibitors of glycosyltransferases
JP4451933B2 (ja) * 1996-12-27 2010-04-14 住友化学株式会社 遺伝子操作による植物へのｐｐｏ阻害性除草剤耐性付与法
US6075134A (en) 1997-05-15 2000-06-13 The Regents Of The University Of California Glycoconjugates and methods
JPH1135593A (ja) 1997-07-18 1999-02-09 Daikin Ind Ltd ２−フルオロフコシル−ｎ−アロイルグルコサミン誘導体及びその中間物、並びにそれらの製造方法
US6670330B1 (en) 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2003085118A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Process for producing antibody composition
AU2004204778B2 (en) 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
WO2006113909A2 (en) 2005-04-19 2006-10-26 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
MXPA05010773A (es) 2003-04-09 2005-12-12 Neose Technologies Inc Metodos de glicopegilacion y proteinas/peptidos producidos por los metodos.
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
US7332334B2 (en) 2003-04-18 2008-02-19 Oklahoma Medical Research Foundation Hematopoietic stem cells treated by in vitro fucosylation and methods of use
US7863042B2 (en) 2003-06-18 2011-01-04 Chugai Seiyaku Kabushiki Kaisha Fucose transporter
JPWO2005035741A1 (ja) 2003-10-09 2006-12-21 協和醗酵工業株式会社 ゲノムが改変された細胞
CN1906203A (zh) 2003-12-23 2007-01-31 普罗吉恩工业有限公司 葡糖胺基聚糖(gag)模拟物
DE102004032421A1 (de) 2004-07-05 2006-01-26 Bayer Cropscience Ag Phenylsubstituierte [1.2]-Oxazin-3,5-dion-und Dihydropyron-Derivate
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
EP2208783A1 (en) 2004-12-22 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Method of producing an antibody using a cell in which the function of fucose transporter is inhibited
PT1945665E (pt) 2005-10-21 2012-04-20 Genzyme Corp Terapêuticas à base de anticorpos com atividade adcc reforçada
EP1957060B1 (en) 2005-11-28 2010-10-20 Ramot at Tel-Aviv University Ltd. Cancer treatment using fts and 2-deoxyglucose
CN104072611A (zh) * 2005-12-21 2014-10-01 维文蒂阿生物公司 与癌症相关的新抗原
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
US20070249014A1 (en) 2006-02-10 2007-10-25 Invitrogen Corporation Labeling and detection of post translationally modified proteins
CN101426508A (zh) 2006-02-24 2009-05-06 得克萨斯系统大学评议会 治疗癌症的己糖化合物
EP1986660A4 (en) 2006-02-24 2009-08-26 Univ Texas HEXOSE COMPOUNDS FOR CANCER TREATMENT
EP1996609B1 (en) 2006-03-22 2016-08-03 The Scripps Research Institute Method of preparing glycopeptides
US9149489B2 (en) 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2009108926A1 (en) 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
JP2010507394A (ja) 2006-10-24 2010-03-11 トルービオン ファーマスーティカルズ インコーポレイテッド 改良免疫糖タンパク質のための物質および方法
EP2457573A1 (en) 2007-02-09 2012-05-30 GlycoMimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and N-Acetyl hexosamines
WO2008131024A1 (en) 2007-04-17 2008-10-30 Board Of Regents, The University Of Texas System Iodo-hexose compounds useful to treat cancer
CN101062939A (zh) 2007-05-17 2007-10-31 北京热景生物技术有限公司 检测肝癌岩藻糖基化高尔基蛋白gp73的装置及试剂盒
CA2702555A1 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
WO2009114641A1 (en) 2008-03-11 2009-09-17 Genentech, Inc. Antibodies with enhanced adcc function
PL2282773T3 (pl) * 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
WO2009143078A2 (en) 2008-05-19 2009-11-26 Board Of Regents, The University Of Texas System Methods of treating brain cancer using hexose compounds
US20110183926A1 (en) 2008-05-23 2011-07-28 University Of Miami Treatment using continuous low dose application of sugar analogs
AU2009268937A1 (en) * 2008-06-16 2010-01-14 Aj Park Compositions for inducing immune responses specific to Globo H and SSEA3 and uses thereof in cancer treatment
EP2411529A4 (en) 2009-03-27 2012-09-19 Zacharon Pharmaceuticals Inc MODULATORS OF BIOSYNTHESIS OF N-BOUND GLYCANS
US20150259371A1 (en) 2010-05-06 2015-09-17 Simon Fraser University Methods and compounds for inhibiting glycosyltransferases
US20110288880A1 (en) 2010-05-07 2011-11-24 Patient Care Automation Services, Inc. Targeted health care messaging
SI2608796T1 (sl) * 2010-08-05 2019-03-29 Seattle Genetics, Inc. Inhibicija proteinske fukozilacije in vivo z uporabo fukoznih analogov
EP2663314A2 (en) 2011-01-11 2013-11-20 The University of Texas M.D. Anderson Cancer Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
US8979675B2 (en) 2012-04-25 2015-03-17 Nike, Inc. Golf ball core having radial appendages
US10350228B2 (en) 2012-08-23 2019-07-16 Seattle Genetics, Inc. Treatment of sickle cell disease and inflammatory conditions
CA3005997A1 (en) 2015-12-04 2017-06-08 Seattle Genetics, Inc. Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992019632A1 (en) * 1991-04-30 1992-11-12 The Biomembrane Institute Trifluoromethyl analogs of fucose and uses thereof
WO1998018805A2 (en) * 1996-10-28 1998-05-07 Novartis Ag Sugar derivatives as sialyl lewis x mimetics

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BECKER ET AL. 'Fucose: biosynthesis and biological function in mammals.' GLYCOBIOLOGY vol. 13, no. 7, 2003, pages 41R - 53R. *
MAY ET AL. "Synthesis and biological activity of potential antimetabolites of L-fucose", Journal of medicinal chemistry, 1 August 1979 (1979-08-01), pages 971-976. *
MAY ET AL. "Synthesis and biological activity of potential antimetabolites of L-fucose", Journal of medicinal chemistry, 1 August 1979 (1979-08-01), pages 971-976. SHEID B ET AL. "Enzymic formation of potential anticancer and antiviral inosine analogs", EXPERIENTIA, BIRKHAEUSER VERLAG. BASEL, CH, vol. 52, no. 9, 1 September 1996 (1996-09-01), pages 878-881, XP008156868. HALTIWANGER ET AL. "Fucose Is on the TRAIL of Colon Cancer", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 137, no. 1, 1 July 2009 (2009-07-01), pages 36-39. BECKER ET AL. 'Fucose: biosynthesis and biological function in mammals.' GLYCOBIOLOGY vol. 13, no. 7, 2003, pages 41R - 53R. *
SHEID, B.; GAETJENS, E.; CHUNG, S. T.; LERNER, L. M.: "Enzymic formation of potential anticancer and antiviral inosine analogs", EXPERIENTIA., SPRINGER BASEL AG, CH, vol. 52, no. 9, 1 September 1996 (1996-09-01), CH, pages 878 - 881, XP008156868, ISSN: 0014-4754, DOI: 10.1007/BF01938874 *

Also Published As

Publication number Publication date
AU2016204495A1 (en) 2016-07-21
US20130129784A1 (en) 2013-05-23
CN103402525B (zh) 2017-03-01
EP2608796B1 (en) 2018-11-21
SI2608796T1 (sl) 2019-03-29
RU2013109415A (ru) 2014-09-10
JP2017149723A (ja) 2017-08-31
MX356671B (es) 2018-06-08
JP2016175909A (ja) 2016-10-06
CN103402525A (zh) 2013-11-20
AU2011285490B2 (en) 2016-04-21
EP2608796A4 (en) 2014-06-11
EP3513794A2 (en) 2019-07-24
US9504702B2 (en) 2016-11-29
NZ606250A (en) 2015-04-24
CA2803388A1 (en) 2012-02-09
ZA201300653B (en) 2014-03-26
IL244019B (en) 2019-09-26
RU2017122482A3 (enExample) 2019-01-30
IL244019A0 (en) 2016-04-21
MX2013001303A (es) 2014-07-24
AU2011285490A1 (en) 2013-01-10
HUE043370T2 (hu) 2019-08-28
KR20190022884A (ko) 2019-03-06
JP6622238B2 (ja) 2019-12-18
ES2711622T3 (es) 2019-05-06
CN107007615A (zh) 2017-08-04
JP2013541503A (ja) 2013-11-14
PT2608796T (pt) 2019-02-25
EP3513794A3 (en) 2019-10-16
US11033561B2 (en) 2021-06-15
CA2803388C (en) 2019-11-05
AU2017279653A1 (en) 2018-01-18
WO2012019165A2 (en) 2012-02-09
US20170035790A1 (en) 2017-02-09
JP6113887B2 (ja) 2017-04-12
KR101950520B1 (ko) 2019-02-20
CY1121419T1 (el) 2020-05-29
JP2020040974A (ja) 2020-03-19
JP5918235B2 (ja) 2016-05-18
TR201902439T4 (tr) 2019-03-21
RU2017122482A (ru) 2019-01-30
IL224487A (en) 2016-07-31
PL2608796T3 (pl) 2019-04-30
WO2012019165A3 (en) 2013-08-15
DK2608796T3 (en) 2019-03-18
KR20130135240A (ko) 2013-12-10
US20210260086A1 (en) 2021-08-26
US20200061091A1 (en) 2020-02-27
EP2608796A2 (en) 2013-07-03
US10342811B2 (en) 2019-07-09

Similar Documents

Publication Publication Date Title
RU2625768C2 (ru) Способы ингибирования фукозилирования белков in vivo с использованием аналогов фукозы
CN111936164B (zh) 癌的治疗和/或预防用药物组合物
CN109912683B (zh) 一种细胞毒素分子、偶联物及其制备方法和应用
US10973922B2 (en) Glycoprotein-toxic payload conjugates
AU2004294842A1 (en) Medicine containing genetically modified antibody against chemokine receptor CCR4
Stoyanova et al. Intensive therapy with gastropodan hemocyanins increases their antitumor properties in murine model of colon carcinoma
EP4445919A1 (en) Antibody-drug conjugate having improved affinity, and preparation method therefor and application thereof
HK40011525A (en) Fucose analogs for inhibition of protein fucosylation in vivo
HK1186659B (en) Inhibition of protein fucosylation in vivo using fucose analogs
HK1186659A (en) Inhibition of protein fucosylation in vivo using fucose analogs
CN117651566A (zh) 用于癌的治疗和/或预防的药品

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner